Trader Talk With Art Cashin 5.4.10
Airtime: Tues. May 4 2010 | 8:50 AM ET
Art Cashin, director of floor operations at UBS, has the buzz from the NYSE.
Similar Posts
Will Health Care Kill the Rally?
Discussing the impact health care reform will have on the markets, with Jim Lacamp, of Macroportfolio Advisors, and David Kelly, of JPMorgan.
Stability of Australia's New Gov't
Discussing the stability of the new Australian government after the Labor Party narrowly secured a one-seat majority, with Nick Sherry, assistant treasurer of Australia and CNBC’s Karen Tso.
Big Money in the Middle East
Investing in the Middle East, with Eyad Mashal, Capital Investment Company and Angus Blair, Beltone Financial.
Impact of IMF Sale on Gold Prices
Airtime: Wed. Feb. 17 2010 | ndard e) ET
The IMF’s move to sell gold in the open market is unlikely to cause a collapse in gold prices, says Sundeep Bhandari, MD & regional head for global markets, Northeast Asia at Standard Chartered. He explains why to CNBC’s Karen Tso & Sri Jegarajah.
Trader Talk With Art Cashin 2.22.10
Art Cashin, head of floor operations at UBS, has the buzz from the NYSE.
Study Identifies Heart Risks in Glaxo's Avandia
Study Identifies Heart Risks in Glaxo’s Avandia. Dr. Steven Nissen, of the Cleveland Clinic, authored a controversial study identifying heart risks in GlaxoSmithKline’s Avandia diabetes drug. He talks to CNBC’s Mike Huckman.